Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;42(1):13-28.
doi: 10.1007/s13402-018-0413-5. Epub 2018 Oct 26.

Cell-free DNA in cancer: current insights

Heidi Fettke  1 , Edmond M Kwan  2   3 , Arun A Azad  2   3
Affiliations
Review

Cell-free DNA in cancer: current insights

Heidi Fettke et al. Cell Oncol (Dordr). 2019 Feb.

Abstract

Background: The field of liquid biopsies in oncology is rapidly expanding, with the application of cell-free circulating tumour DNA (ctDNA) showing promise in this era of precision medicine. Compared with traditional clinical and radiographic tumour monitoring methods, the analysis of ctDNA provides a minimally-invasive and technically feasible approach to assess temporal and spatial molecular evolutions of the tumour landscape. The constantly advancing technological platforms available for ctDNA extraction and analysis allow greater analytical sensitivities than ever before. The potential translational impact of ctDNA as a blood-based biomarker for the identification, characterization and monitoring of cancer has been demonstrated in numerous proof-of-concept studies, with ctDNA analysis beginning to be applied clinically across multiple facets of oncology.

Conclusions: In this review we discuss the biology, recent advancements, technical considerations and clinical implications of ctDNA in the context of cancer, and highlight important challenges and future directions for the integration of ctDNA into standardised patient care.

Keywords: Cell-free DNA; Circulating tumour DNA; cancer; liquid biopsy.

PubMed Disclaimer

References

    1. M. Ilié, P. Hofman, Pros: Can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res 5, 420–423 (2016) - DOI - PubMed - PMC
    1. N. Krishnamurthy, E. Spencer, A. Torkamani, L. Nicholson, Liquid biopsies for cancer: Coming to a patient near you. J Clin Med 6, 3 (2017) - DOI - PMC
    1. M.J. Overman, J. Modak, S. Kopetz, R. Murthy, J.C. Yao, M.E. Hicks, J.L. Abbruzzese, A.L. Tam, Use of research biopsies in clinical trials: Are risks and benefits adequately discussed? J Clin Oncol 31, 17–22 (2013) - DOI - PubMed
    1. P.A. VanderLaan, N. Yamaguchi, E. Folch, D.H. Boucher, M.S. Kent, S.P. Gangadharan, A. Majid, M.A. Goldstein, M.S. Huberman, O.N. Kocher, D.B. Costa, Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 84, 39–44 (2014) - DOI - PubMed
    1. S.Q. Wong, J. Li, A.Y.C. Tan, R. Vedururu, J.-M.B. Pang, H. Do, J. Ellul, K. Doig, A. Bell, G.A. McArthur, S.B. Fox, D.M. Thomas, A. Fellowes, J.P. Parisot, A. Dobrovic, Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genet 7, 23 (2014)

Substances

LinkOut - more resources